Gefitinib Completed Phase 4 Trials for Caucasian Patients With EGFR Mutation Positive Advanced NSCLC Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT01203917Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC